DT
Defence Therapeutics Inc.
DTCFF · OTC
$0.28 +0.21% (+$0.00)
1M -16.12%
Market Cap $30.5M
P/E Ratio -
Div. Yield -
ROE 1,379.11%
Bulios Fair Price
$0.23
18.9% downside
Current Price
$0.28
Undervalued Fair Value Overvalued
According to Bulios Fair Price, DTCFF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
30 /100
Expensive P/B 5.62x
P/E N/A
EV/EBITDA N/A
Growth
-
N/A EPS growth N/A
Rev. growth N/A
Book val. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
FCF margin N/A
Quality
0 /100
Poor ROIC 52.21%
ROE 1,379.11%
Asset turnover 0.00x
Debt
69 /100
Low Debt/Equity 0.29x
Current ratio 3.37x
Int. coverage -19.19x
Stability
18 /100
Unstable Beta 1.35x
EPS volatility 88.26%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about DTCFF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Amie Phinney
Employees
1,300
Headquarters
Montreal